Crofab Market Report 2026

Crofab Market Overview

• The Crofab market growth in the historic period has been driven by clinical effectiveness of crofab, established emergency protocols for snakebites • Market expansion is supported by expansion of emergency care access, rising awareness of snakebite management • Growth Driver: Impact Of Rising Snakebite Incidents On The Growth Of The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Crofab Market?

Crofab refers to a specific snakebite antivenom used to treat envenomations from pit vipers, such as rattlesnakes, copperheads, and cottonmouths. Crofab is utilized in the treatment of envenomation from pit viper snakebites by administering the antivenom intravenously to neutralize the venom and reduce symptoms such as swelling, pain, and potential organ damage. The main types of indications of crofab are hemotoxic effects, local tissue damage, and systemic toxicity. Hemotoxic effects refer to the impact of venom on the blood and cardiovascular system, including destruction of red blood cells, disruption of blood clotting, and damage to blood vessels. It is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies, catering to various end users such as hospitals, clinics, ambulatory care, and home care.

What Is The Crofab Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of emergency care access, rising awareness of snakebite management, improved rural healthcare reach, government investment in antivenom programs, advancements in biologic antitoxin production. Major trends in the forecast period include sustained demand for snakebite antivenom, rising focus on emergency envenomation treatment, expansion of trauma and emergency care infrastructure, improved availability of targeted antivenoms, growing awareness of rapid snakebite intervention.

Global Crofab Market Segmentation

1) By Clinical Indication: Hemotoxic Effects, Local Tissue Damage, Systemic Toxicity 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies 3) By End Users: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Crofab Market?

The rising snakebite incidents are expected to propel the growth of the carofab market going forward. Snakebite incidents refer to occurrences where individuals are bitten by snakes, which may be venomous or non-venomous. The rising snakebite incidents are due to increased human encroachment into wildlife habitats, climate change altering snake behavior and habitats, growing rural populations in endemic regions, and greater outdoor recreational activities in snake-prone areas. Carofab helps in snakebite incidents by providing a rapid and effective antidote to venom, neutralizing toxins, and preventing severe complications, thereby reducing the risk of death and improving patient outcomes in critical snakebite situations. For instance, in October 2023, according to a report published by the National Library of Medicine, in Australia, approximately 3,000 snakebites occurred each year, leading to around 500 hospitalizations and an average of two fatalities annually. Therefore, the increased incidence of snakebites is driving growth in the carofab market. The rising healthcare expenditure is expected to propel the growth of the carofab market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare services and products within a specific time frame, usually measured annually. Rising healthcare expenditure is driven by factors such as an aging population, increasing prevalence of chronic diseases, advancements in medical technology, higher costs of pharmaceuticals, and the expansion of healthcare access and services. Healthcare expenditure helps crofab by providing the necessary funding for research, production, and distribution of this life-saving snakebite antivenom, ensuring that it remains accessible to those in need while supporting ongoing advancements in medical treatments and maintaining healthcare system sustainability. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with the growth of 0.9% in 2022. Therefore, the rising healthcare expenditure is driving growth in the carofab market. The increasing number of emergency care facilities is expected to boost the growth of the carofab market going forward. Emergency care facilities refer to healthcare establishments that provide immediate medical attention to individuals with acute illnesses or injuries that require urgent intervention. The increase in emergency care facilities are due to rising incidences of chronic and acute illnesses, improved access to healthcare, and the need for timely medical interventions in critical situations. CroFab, an antivenom specifically designed to treat venomous snakebites from North American pit vipers, supports emergency care facilities by enabling rapid and effective neutralization of venom, reducing the severity of symptoms, preventing complications, and improving patient outcomes in critical snakebite emergencies. For instance, in September 2023, according to a report published by the Royal College of Emergency Medicine, a UK-based independent professional association, during the 2022/23 period, A&E departments across England recorded approximately 25.3 million attendances, reflecting a 4% rise compared to the previous year. Therefore, the increasing number of emergency care facilities is driving growth in the carofab market.

Key Players In The Global Crofab Market

Major companies operating in the crofab market are SERB Specialty Pharmaceuticals

Regional Insights

North America was the largest region in the crofab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Crofab Market?

The crofab market consists of sales of products including antigen-binding fragment (Fab), and polyclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Crofab Market Report 2026?

The crofab market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the crofab industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.